Deliver Consulting Limited | Back to main site

发言嘉宾

  • Hua Gong

    转化医学与临床生物标记物, 高级副总裁

    再鼎医药

    发言嘉宾简介:

    Hua Gong, M.D., Ph.D., has been appointed as SVP, Translational Medicine. Dr. Gong has more than 20 years of experience in drug discovery and development, particularly in personalized medicine and clinical development. Dr. Gong joined Zai Lab from Adagene where she served as the Chief Operating Officer and Head of Clinical Development and Precision Medicine. She oversaw all the clinical development programs and successfully initiated several new trials at Adagene.

    Before joining Adagene, Dr. Gong worked at Novartis Navigate Biopharma where she served as Senior Director, Head of Genomics Biomarker Department. She directly contributed to the U.S. Food and Drug Administration approvals of seven oncology drugs since 2013: Tabrecta™ (capmatinib), Piqray® (alpelisib), Tafinlar® (dabrafenib) + Mekinist® (trametinib) for NSCLC, Kisqali® (ribociclib), Kymriah® (tisagenlecleucel) and Zykadia® (ceritinib).

    Prior to Novartis, she was Executive Director of IVD & CDx at Premier Research Group, where she effectively enabled oncology development programs of their pharmaceutical partners by providing precision medicine solutions. At Prometheus Therapeutics & Diagnostics, Dr. Gong was Associate Director of the Clinical Development Department, where she was responsible for overseeing multiple clinical studies. She successfully contributed to the expansion of Proleukin clinical applications. Additionally, Dr. Gong worked at Pfizer for over 10 years in a variety of positions of increasing responsibility. In her last position at Pfizer, Dr. Gong managed a multi-disciplinary team including in-vitro/vivo biology, PDM, drug safety and biomarker research groups. She was a key contributor to two drugs that entered clinical development. Dr. Gong received her medical training from An Hui Medical University, her M.S. from Sun Yat-Sen University of Medical Sciences and her Ph.D. in cancer biology from Wayne State University.